A devastating infection with a 97% mortality rate may have met its match. Recent breakthrough research reveals promising new treatments for Primary Amebic Meningoencephalitis (PAM), the fatal brain infection caused by Naegleria fowleri.

Groundbreaking Discovery in PAM Treatment

A pivotal study published in PLOS Neglected Tropical Diseases has identified CYP51 as a critical target for treating PAM. The research demonstrates how existing antifungal medications could be repurposed to fight this deadly infection, potentially saving lives.

The findings are striking: in laboratory tests, these antifungal compounds proved ten times more effective than current treatments, with results visible within just 8 hours. Founders of Arome Science have lead metabolomics analysis in this study.